Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophosphamide-based regimens

被引:44
作者
Ridola, Vita [1 ,2 ]
Fawaz, Oumaya [1 ]
Aubier, Francoise [3 ]
Bergeron, Christophe [4 ]
de Vathaire, Florent [5 ]
Pichon, Fabienne [6 ]
Orbach, Daniel [7 ]
Gentet, Jean Claude [8 ]
Schmitt, Claudine [9 ]
Dufour, Christelle [1 ]
Oberlin, Odile [1 ]
机构
[1] Inst Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France
[2] Univ Cattolica Sacro Cuore, Dept Pediat Oncol, Rome, Italy
[3] Ctr Therapeut, Dept Oncol, Margency, France
[4] Ctr Leon Berard, Dept Pediat Oncol, F-69373 Lyon, France
[5] INSERM, U605, Villejuif, France
[6] Ctr Oscar Lambret, Dept Pediat, F-59020 Lille, France
[7] Inst Curie, Dept Pediat Oncol, Paris, France
[8] Univ Hosp La Timone, Dept Pediat Oncol, Marseille, France
[9] Univ Hosp, Dept Hematol & Oncol, Nancy, France
关键词
Ifosfamide; Cyclophosphamide; Fertility; Male; Toxicity; Gonads; Long-term sequelae; MALE GONADAL-FUNCTION; HODGKINS-DISEASE; PEDIATRIC ONCOLOGY; CHEMOTHERAPY; ADOLESCENCE; THERAPY; SARCOMA; DAMAGE; RHABDOMYOSARCOMA; OSTEOSARCOMA;
D O I
10.1016/j.ejca.2009.01.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study aimed at comparing gonadal toxicity of ifosfamide versus cyclophosphamide received during childhood. Methods: The evaluation was based on basal FSH measurement. LH and testosterone were also measured in most of the patients. One hundred patients had received ifosfamide and 59 had received cyclophosphamide. Results: Median age at treatment was 11.2 years. The median interval since treatment was 10.7 years (range 4.1-20.2) and median age at evaluation was 21.4 years (17.5-36.1). The median dose of ifosfamide and of cyclophosphamide was 54 g/m(2) (18-114) and 8.3 g/m(2) (4.6-22), respectively. All but two males had normal testosterone levels. FSH was abnormal in 28/59 patients (47.5%) after receiving cyclophosphamide and was within the normal range in 94/100 patients (94%) after receiving ifosfamide. Conclusions: These results show that ifosfamide is associated with a lower risk of gonadal damage than cyclophosphamide. The risk of abnormal FSH increased with the cumulative dose of cyclophosphamide. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:814 / 818
页数:5
相关论文
共 35 条
  • [11] 2-Y
  • [12] Howell S J, 2005, J Natl Cancer Inst Monogr, P12
  • [13] Inhibin B as a serum marker of spermatogenesis: Correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men
    Jensen, TK
    Andersson, AM
    Hjollund, NHI
    Scheike, T
    Kolstad, H
    Giwercman, A
    Henriksen, TB
    Ernst, E
    Bonde, JP
    Olsen, J
    McNeilly, A
    Groome, NP
    Skakkebaek, NE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (12) : 4059 - 4063
  • [14] Kalifa C, 1993, Cancer Treat Res, V62, P347
  • [15] Kenney LB, 2001, CANCER, V91, P613, DOI 10.1002/1097-0142(20010201)91:3<613::AID-CNCR1042>3.0.CO
  • [16] 2-R
  • [17] Male reproductive health after childhood cancer
    Lahteenmaki, P. M.
    Arola, M.
    Suominen, J.
    Salmi, T. T.
    Andersson, A. M.
    Toppari, J.
    [J]. ACTA PAEDIATRICA, 2008, 97 (07) : 935 - 942
  • [18] SFOPOS94:: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
    Le Deley, Marie-Cecile
    Guinebretiere, Jean-Marc
    Gentet, Jean-Claude
    Pacquement, Helene
    Pichon, Fabienne
    Marec-Berard, Perrine
    Entz-Werle, Natacha
    Schmitt, Claudine
    Brugieres, Laurence
    Vanel, Daniel
    Dupouy, Noelle
    Tabone, Marie-Dominique
    Kalifa, Chantal
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) : 752 - 761
  • [19] Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma
    Longhi, A
    Macchiagodena, M
    Vitali, G
    Bacci, G
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (04) : 292 - 296
  • [20] Mackie EJ, 1996, MED PEDIATR ONCOL, V27, P74, DOI 10.1002/(SICI)1096-911X(199608)27:2<74::AID-MPO2>3.0.CO